Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Laura C. Coates; Robert Landewé; Iain B. McInnes; Philip J. Mease; Christopher T. Ritchlin; Yoshiya Tanaka; Akihiko Asahina; Frank Behrens; Dafna D. Gladman; Laure Gossec; Ana‐Maria Orbai; Alice B. Gottlieb; Richard B. Warren; Barbara Ink; Rajan Bajracharya; Vishvesh Shende; Jason Coarse; Joseph F. Merola

doi:10.1136/rmdopen-2023-003855

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from week 16 to 52.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coates et al. (2024) studied this question.

synapsesocial.com/papers/69d7e4e37392c8ce61bee1d9 https://doi.org/10.1136/rmdopen-2023-003855

View Full Paper

Ask AI

Bookmark

Share

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Ask about this paper

Abstract

Discussion

Cite This Study

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading